Frontrunner in Translation: Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a four-repeat tau proteinopathy. Abnormal tau deposition is not unique for PSP and is the basic pathologic finding in some other neurodegenerative disorders such as Alzheimer's disease (AD), age-related tauopathy, frontotemporal degeneration, corticobasal...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-10-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.01125/full |
| _version_ | 1818136632982765568 |
|---|---|
| author | Ali Shoeibi Nahid Olfati Irene Litvan |
| author_facet | Ali Shoeibi Nahid Olfati Irene Litvan |
| author_sort | Ali Shoeibi |
| collection | DOAJ |
| description | Progressive supranuclear palsy (PSP) is a four-repeat tau proteinopathy. Abnormal tau deposition is not unique for PSP and is the basic pathologic finding in some other neurodegenerative disorders such as Alzheimer's disease (AD), age-related tauopathy, frontotemporal degeneration, corticobasal degeneration, and chronic traumatic encephalopathy. While AD research has mostly been focused on amyloid beta pathology until recently, PSP as a prototype of a primary tauopathy with high clinical-pathologic correlation and a rapid course is a crucial candidate for tau therapeutic research. Several novel approaches to slow disease progression are being developed. It is expected that the benefits of translational research in this disease will extend beyond the PSP population. This article reviews advances in the diagnosis, epidemiology, pathology, hypothesized etiopathogenesis, and biomarkers and disease-modifying therapeutic approaches of PSP that is leading it to become a frontrunner in translation. |
| first_indexed | 2024-12-11T09:43:30Z |
| format | Article |
| id | doaj.art-8cd69b1c6c3345b5bec4cbc7933210a1 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-11T09:43:30Z |
| publishDate | 2019-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-8cd69b1c6c3345b5bec4cbc7933210a12022-12-22T01:12:37ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-10-011010.3389/fneur.2019.01125493674Frontrunner in Translation: Progressive Supranuclear PalsyAli Shoeibi0Nahid Olfati1Irene Litvan2Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IranUC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, United StatesProgressive supranuclear palsy (PSP) is a four-repeat tau proteinopathy. Abnormal tau deposition is not unique for PSP and is the basic pathologic finding in some other neurodegenerative disorders such as Alzheimer's disease (AD), age-related tauopathy, frontotemporal degeneration, corticobasal degeneration, and chronic traumatic encephalopathy. While AD research has mostly been focused on amyloid beta pathology until recently, PSP as a prototype of a primary tauopathy with high clinical-pathologic correlation and a rapid course is a crucial candidate for tau therapeutic research. Several novel approaches to slow disease progression are being developed. It is expected that the benefits of translational research in this disease will extend beyond the PSP population. This article reviews advances in the diagnosis, epidemiology, pathology, hypothesized etiopathogenesis, and biomarkers and disease-modifying therapeutic approaches of PSP that is leading it to become a frontrunner in translation.https://www.frontiersin.org/article/10.3389/fneur.2019.01125/fullprogressive supranuclear palsytauopathytranslational researchepidemiologyetiopathogenesisbiomarker |
| spellingShingle | Ali Shoeibi Nahid Olfati Irene Litvan Frontrunner in Translation: Progressive Supranuclear Palsy Frontiers in Neurology progressive supranuclear palsy tauopathy translational research epidemiology etiopathogenesis biomarker |
| title | Frontrunner in Translation: Progressive Supranuclear Palsy |
| title_full | Frontrunner in Translation: Progressive Supranuclear Palsy |
| title_fullStr | Frontrunner in Translation: Progressive Supranuclear Palsy |
| title_full_unstemmed | Frontrunner in Translation: Progressive Supranuclear Palsy |
| title_short | Frontrunner in Translation: Progressive Supranuclear Palsy |
| title_sort | frontrunner in translation progressive supranuclear palsy |
| topic | progressive supranuclear palsy tauopathy translational research epidemiology etiopathogenesis biomarker |
| url | https://www.frontiersin.org/article/10.3389/fneur.2019.01125/full |
| work_keys_str_mv | AT alishoeibi frontrunnerintranslationprogressivesupranuclearpalsy AT nahidolfati frontrunnerintranslationprogressivesupranuclearpalsy AT irenelitvan frontrunnerintranslationprogressivesupranuclearpalsy |